Gil-Jimenez, Alberto http://orcid.org/0000-0003-0643-6676
van Dijk, Nick
Vos, Joris L. http://orcid.org/0000-0002-8318-5455
Lubeck, Yoni
van Montfoort, Maurits L.
Peters, Dennis http://orcid.org/0000-0003-2931-3097
Hooijberg, Erik http://orcid.org/0000-0002-4482-2191
Broeks, Annegien
Zuur, Charlotte L. http://orcid.org/0000-0002-1777-012X
van Rhijn, Bas W. G.
Vis, Daniel J.
van der Heijden, Michiel S. http://orcid.org/0000-0002-4407-7881
Wessels, Lodewyk F. A. http://orcid.org/0000-0002-1656-6995
Funding for this research was provided by:
Bristol-Myers Squibb (n/d)
Article History
Received: 9 May 2023
Accepted: 28 February 2024
First Online: 21 March 2024
Competing interests
: MvdH received research funding from Bristol Myers Squibb, AstraZeneca, 4SC and Roche, and consultancy fees from Bristol Myers Squibb, Roche, Merck Sharp & Dohme, Merck, AstraZeneca, Pfizer, Janssen and Seattle Genetics which were all paid to the Netherlands Cancer Institute. LFAW received research funding from Genmab, which was all paid to the Netherlands Cancer Institute. CLZ received research financial support from Bristol Myers Squibb to fund the IMCISION trial, which was all paid to the Netherlands Cancer Institute. The rest of the authors have no conflicts of interest related to this work.